YAN Miao 1,2, FAN Xin-rong3*, HE Qing-hu3, GONG Hui1,2
1 The Second Xiangya Hospital,Central South University,Changsha 410011,China;2 Institute of Clinical Pharmacy,Central South University,Changsha 410011,China; 3 Hunan University of Chinese Medicine,Changsha 410007,China
Abstract��
Objective To study the effect of Kelong capsule on kidney deficiency and blood stasis rats prostatic hyperplasia and the prostatic hyperplasia related protein and cell factors. METHODS Establish rat model for benign prostate hyperplasia with kidney deficiency and blood stasis syndrome and observe rats prostate and prostate correlation factors of blank control (A),model (B),the finateride (C),high,medium and low dose kelong (D,E,F). RESULTS ��The prostate wet weight and prostate index of rats in groups C-F were significantly lower than that in group B (P<0.05). ��Compared with group B,Ki-67 integral optical density in prostate tissue obviously decreased in group C,E,F (P<0.01),group D has no significant difference (P>0.05). ��Compared with group B,bFGF integral optical density in prostate tissue in group C,D,E and F decreased obviously (P<0.01)but compared with group C,those in group D,E and F were significantly increased (P<0.05). ��Compared with group B,VEGF mRNA expression in prostate tissue in group C,D,E and F were reduced (P<0.05)�� but those in group D,E and F were more than in C group (P<0.05). CONCLUSION Kelong capsule can dose-dependently inhibit prostatic hyperplasia in rats possibly through the inhibition of prostatic hyperplasia related protein and cell factors.
YAN Miao-,
,
FAN Xin-Rong-* etc
.Effect of Kelong Capsule on Ki-67, bFGF and VEGF mRNA Expression in Benign Prostate Hyperplasia Tissues from Rats[J] Chinese Pharmaceutical Journal, 2013,V48(6): 436-440
��
[1]
HE Q H. Discussion of the mechanism of benign prostate hyperplasia kidney deficiency and blood stasis. J Tradit Chin Med Univ Hunan(������ҽѧԺѧ��),1997,17��2��:8-10.
[2]
ZHAO J Y,HE Q H. Kidney deficiency and blood stasis are the basic pathogenesis of prostate hyperplasia .J New Chin Med(����ҽ),2011,43��2��:8-9.
[3]
FAN X R,SUN T,HE Q H. Clinical study of Kelong Capsule in treating prostatic hyperphasia . Med Recap(ҽѧ����) ,2010,16��16��:2545-2547.
[4]
GERDES J,SCHWAB U,LEMKE H,et al.Produetion of mouse monoclonal antibody reactive with human nuclear antigen associated with cell proliferation. Int J Cancer,1983,31(1):13-16.
[5]
DENG F M. Proliferation and apoptosis ststes in benugn prostatic hyperplasia. Chin J Surg(�л������־),1996,34(10):620-622.
[6]
PENG J,ZHANG Q,YU W,et al. Effect of angiotensin II on prostate cell proliferation and apoptosis in rats. Chin J Urol(�л����������־),2006,27(9):615-617.
[7]
JIN J,NA Y Q. Pygeum of ricanum extract-tadenan in the treatment of benign prostatic hyperplasia. Chin J Urol(�л����������־),1997,18(5):293-295.
[8]
JIN L L,LI K,YANG Y F,et al. Research progress of benign prostatic hyperplasia drug targets . Chin Pharm J(�й�ҩѧ��־),2009,44 (3): 161-165.
[9]
TUTRONE R F,BALL R A,ORNITZ D M,et al. Benign prostatic hyperplasia in a transgenic mouse: A new hormonally sensitive investigatory model . J Urol,1993,149(3):633-639.
[10]
SHERWOOD E R,LEE C.Epidermal growth factor-related peptides and the epidermal growth receptor in normal and malignant prostate. World J Urol,1995,13(5):290-296.
[11]
ROBERTSON C N,ROBERTSON K M,HERZBERG A J,et al.Differential immnunoreactivity of transforming growth factor alpha in benign,dysplastic and malignant prostatic tissues. Surg Oncol,1994,3(4):237-242.
[12]
NASHI N,OYA H,MATSUMOTO K,et al.Changes in gene expression of growth factors and their receptors during castration-induced involution and androgen-induced regrowth of rat prostates . Prostate,1996,28(3):139-152.
3.0.CO;2-A target="_blank">
[13]
WU X H,LIANG N N. The expression of VEGF,Flt-1 and MVD in benign prostatic hyperplasia . J Chongqing Med Univ(����ҽ�ƴ�ѧѧ��),2004,29��5��:608-611.
2013, Vol. 48 
